Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Tevogen Bio Holdings Inc. (TVGN)

$4.49 +1.81% NASDAQ: TVGN · 15-min delayed
  • WARREN, New Jersey
  • Public · NASDAQ: TVGN
  • 18 employees
$43.8MMarket cap
-$26.3MNet income
18Employees
TVGNNASDAQ
2024IPO

About Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$26.3M
Total assets
$4.4M
Market cap
$43.8M
Operating margin
13363.0%
Net margin
13432.0%

Source: SEC EDGAR · updated Jun 8, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
-$195.6K
Operating expenses
$26.1M
Operating income
-$26.1M
Income tax
$4.8K
Net income
-$26.3M
EPS (basic)
$-8.08
EPS (diluted)
$-8.08

Balance sheet

Total assets
$4.4M
Current assets
$1.5M
Total liabilities
$12.6M
Current liabilities
$7.1M
Shareholders’ equity
-$8.2M

Cash flow

Operating cash flow
-$12.3M
Investing cash flow
$666.2K
Financing cash flow
$11.7M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: TVGN
$4.49 +1.81%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$3.89 $63.00

52-week range

Market cap
$43.8M
EPS (diluted)
$-8.08
Shares outstanding
9.8M
Open
Day range
Prev close
Volume
IPO date
Feb 15, 2024

Tevogen Bio Holdings Inc. (TVGN) Stock Price

  • Reported a net loss of $26.3M.
  • Trading 93% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Tevogen Bio Holdings Inc..

Write a review
Newsroom

News about Tevogen Bio Holdings Inc.

News & sentiment via Polygon.io

FAQ

Tevogen Bio Holdings Inc.: frequently asked questions

Is Tevogen Bio Holdings Inc. an American company?

Tevogen Bio Holdings Inc. is a US-based company headquartered in Warren, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Tevogen Bio Holdings Inc. headquartered?

Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey, United States.

Is Tevogen Bio Holdings Inc. publicly traded?

Yes — Tevogen Bio Holdings Inc. is a publicly traded company. Its stock trades under the ticker symbol TVGN on the NASDAQ.

What does Tevogen Bio Holdings Inc. do?

Tevogen Bio Holdings Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →